Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M8,102Revenue (TTM) $M458Net Margin (%)-26.5Altman Z-Score22.8
Enterprise Value $M7,651EPS (TTM) $-0.9Operating Margin %-45.1Piotroski F-Score2
P/E(ttm)--Beneish M-Score-1.8Pre-tax Margin (%)-26.5Higher ROA y-yN
Price/Book12.210-y EBITDA Growth Rate %-3.2Quick Ratio3.7Cash flow > EarningsN
Price/Sales17.75-y EBITDA Growth Rate %1.2Current Ratio4.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-14.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-19.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M144ROIC % (ttm)-190.3Gross Margin Increase y-yN

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

SGEN is held by these investors:



SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SIEGALL CLAY BPresident and CEO 2018-01-11Sell18,832$51.717.6view
SIEGALL CLAY BPresident and CEO 2017-12-11Sell18,832$55.40.43view
DOBMEIER ERICCOO 2017-12-04Sell3,729$58.75-5.29view
HIMES VAUGHN BChief Technical Officer 2017-11-30Sell10,000$59.97-7.22view
DOBMEIER ERICCOO 2017-11-17Sell35,000$58.25-4.48view
LIPPMAN MARC EDirector 2017-11-15Sell3,000$58.07-4.18view
SIEGALL CLAY BPresident and CEO 2017-11-10Sell18,832$58-4.07view
SIMPSON TODD ECFO 2017-11-01Sell39,385$60.91-8.65view
SIEGALL CLAY BPresident and CEO 2017-10-11Sell18,832$61.18-9.06view
SIEGALL CLAY BPresident and CEO 2017-09-11Sell18,832$53.494.02view

Press Releases about SGEN :

Quarterly/Annual Reports about SGEN:

News about SGEN:

Articles On GuruFocus.com
Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immu Nov 08 2017 
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Oct 10 2017 
Green Monday for Capital Markets Around the Globe Oct 02 2017 
Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothel Jun 05 2017 
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Actio Mar 08 2017 
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsui Mar 05 2017 
IMPORTANT SEATTLE GENETICS INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP remi Feb 28 2017 
7 Stocks That Are Beating the Market Feb 21 2017 
Insiders Buy Herbalife, Sell MasterCard Nov 05 2016 
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK